BeOne Medicines shares surge after strong first-quarter earnings

7 articles · Updated · MarketWatch · May 7

Hong Kong-listed shares jumped as much as 7.0% and Shanghai-listed shares 6.1% after GAAP net income rose to $227.4 million from $1.3 million a year earlier.
Revenue climbed 35%, driven by flagship cancer drugs that BeOne said now lead the US market and are expanding in Europe, while adjusted earnings per share reached $3.24.
The drugmaker raised fiscal 2026 guidance as it expands globally from roots in China, with operations across the US, China and Europe and a recent $1.9 billion Huahui Health licensing deal.

Can BeOne win the patent wars threatening its billion-dollar cancer drug?

Is BeOne's new $1.9 billion 'three-in-one' antibody the future of cancer therapy?

Is BeOne’s strategic move from China to Switzerland the new global playbook?